Hernexeos (zongertinib) — Medica
Non-small cell lung cancer (NSCLC) with HER2 (ERBB2) activating mutation
Initial criteria
- age ≥ 18 years
- unresectable or metastatic disease
- has human epidermal growth factor receptor 2 (HER2) [ERBB2] activating mutation
- mutation detected by an approved test
- has received at least one prior systemic therapy
Approval duration
1 year